Tzu-Hsiu Tsai
Overview
Explore the profile of Tzu-Hsiu Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, et al.
J Formos Med Assoc
. 2024 Dec;
PMID: 39694766
Background: PD-L1 is associated with poor efficacy of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in untreated EGFR-mutant non-small-cell lung cancer (NSCLC). Whether PD-L1 is...
2.
Huang C, Chou H, Chang H, Yang C, Lin S, Chang L, et al.
ERJ Open Res
. 2024 Mar;
10(2).
PMID: 38469375
Background: The effectiveness of using a spray nozzle to deliver lidocaine for superior topical airway anaesthesia during non-sedation flexible bronchoscopy (FB) remains a topic of uncertainty when compared with conventional...
3.
Lin Y, Ho C, Hsu W, Liao W, Yang C, Yu C, et al.
Cancer Med
. 2023 Dec;
13(1):e6870.
PMID: 38140788
Introduction: According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell-free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine...
4.
Huang D, Liao B, Hsu W, Yang C, Lin Y, Wu S, et al.
Oncology
. 2023 Oct;
102(4):318-326.
PMID: 37778345
Introduction: In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events....
5.
Yang C, Shih J, Liao W, Ho C, Hsu C, Tsai T, et al.
Eur J Cancer
. 2023 Sep;
193:113310.
PMID: 37722270
Background: Next-generation sequencing (NGS) of plasma cell-free DNA identifies driver mutations in advanced non-small cell lung cancer (NSCLC) and may complement routine molecular evaluation. The utility of liquid NGS at...
6.
Tsai T, Gow C, Liu Y, Tsai M, Chang T, Wu S, et al.
Cancer Med
. 2023 May;
12(13):14511-14525.
PMID: 37212485
Objective: In lung cancer patients, most deaths are caused by the distant dissemination of cancer cells. Epithelial-mesenchymal transition (EMT) and collective cell migration are distinct and important mechanisms involved in...
7.
Huang C, Lin C, Su T, Yang C, Tsai T, Hsu C, et al.
BMC Cancer
. 2023 Mar;
23(1):234.
PMID: 36915101
Background: The T790M mutation is the major resistance mechanism to first- and second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR (ddPCR) for...
8.
Chang C, Hsieh M, Shih J, Lee Y, Liao W, Hsu C, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221133889.
PMID: 36324732
Objectives: A definitive diagnosis of pulmonary sarcomatoid carcinoma cannot be made with small biopsies. In clinical practice, a diagnosis of advanced non-small-cell lung cancer with spindle cell and/or giant cell...
9.
Liao B, Hsu W, Lee J, Yang C, Tsai T, Liao W, et al.
JTO Clin Res Rep
. 2021 Sep;
2(1):100099.
PMID: 34589970
Introduction: Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard of care...
10.
Hsu C, Tsai T, Huang C, Yang C, Liao W, Ho C, et al.
Lung Cancer
. 2021 Apr;
156:50-58.
PMID: 33894494
Objectives: Circulating tumor cells (CTCs) are associated with tumor spread, whereas cancer stem cells may be related to drug resistance. However, few studies have analyzed the levels of circulating cancer...